Ocugen, Inc.
11 Great Valley Parkway
Malvern, PA 19355
United States
484 328 4701
https://www.ocugen.com
版塊: Healthcare
行業: Biotechnology
全職員工: 65
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Shankar Musunuri M.B.A., Ph.D. | Co-Founder, CEO & Chairman | 1.2M | 1.26M | 1964 |
| Dr. Uday B. Kompella Ph.D. | Co-founder & Independent Director | 56.72k | 無 | 1967 |
| Mr. Michael Breininger CPA, M.B.A. | Interim Chief Accounting Officer & Principal Financial Officer and Corporate Controller | 無 | 無 | 1982 |
| Dr. Arun Upadhyay Ph.D. | Chief Scientific Officer and Head of Research & Development | 無 | 無 | 1983 |
| John Kouch J.D. | General Counsel | 無 | 無 | 無 |
| Ms. Tiffany J. Hamilton M.B.A. | Head of Corporate Communications | 無 | 無 | 無 |
| Dr. Durgaprasad Annavajjula Ph.D. | VP, Head of Program Management & Chief of Staff | 無 | 無 | 無 |
| Mr. Michael Shine M.B.A. | Senior Vice President of Commercial | 無 | 無 | 無 |
| Ms. Jyothy Pillai M.S. | Head of Regulatory & Quality | 無 | 無 | 無 |
| Dr. Huma Qamar CMI, M.D., M.P.H. | Chief Medical Officer | 無 | 無 | 無 |
描述
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
公司管治
截至 2024年4月1日 止，Ocugen, Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：5；董事會：7；股東權利：8；現金賠償：10。
